Why is Astec Lifescienc falling/rising?

As of 20-Aug, Astec Lifesciences Ltd is experiencing a decline in its stock price, currently at 832.70, which reflects a decrease of 2.3 points or 0.28%. The stock has underperformed its sector today by 1.02%. In terms of recent performance, the stock has shown a 4.09% increase over the past week, but it has significantly underperformed over the longer term, with a 7.11% decline in the last month and a staggering 31.30% drop over the past year. The company has reported negative results for the last five consecutive quarters, with operating cash flow at its lowest and a high debt to EBITDA ratio indicating weak long-term fundamental strength. This has contributed to a perception of risk, as the stock is trading at risky valuations compared to its historical performance.
In the broader market context, while the Sensex has gained 1.64% over the past week, Astec Lifesciences has lagged behind, reflecting its consistent underperformance against the benchmark over the last three years. The stock's year-to-date decline of 17.14% contrasts sharply with the Sensex's 4.76% increase, highlighting the challenges the company faces in generating returns for its shareholders. The falling investor participation, evidenced by a significant drop in delivery volume, further underscores the lack of confidence in the stock, contributing to its downward price movement.